Franco-Nevada Corporation has agreed to acquire an additional A$170 million (about $122 million) royalty interest from Minerals 260 Limited, raising its total gross royalty on the Bullabulling Gold Project in Western Australia to 3.90%. The company also committed to a A$30 million (approximately $22 million) equity investment in Minerals 260. This deal supports the development of one of Australia's largest near-term gold projects, which has a resource of 4.4 million ounces indicated and aims for first production by the second half of 2028. The financing will help Minerals 260 complete a definitive feasibility study and reach a final investment decision in early 2027, with plans to expand production capacity and extend mine life to 19 years.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
